Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Pietzak
Dr. Eugene Pietzak is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 16 years. He is one of 87 doctors at Memorial Sloan Kettering Cancer Center and one of 16 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Urology. He has more than 80 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2015 - 2017
University of Pennsylvania Health SystemResidency, Urology, 2011 - 2015
Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 2010 - 2011
Stony Brook University Health Sciences Center School of MedicineClass of 2010
Certifications & Licensure
NJ State Medical License 2021 - 2027
NY State Medical License 2015 - 2026
PA State Medical License 2010 - 2015
American Board of Urology Urology
Clinical Trials
- Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment Start of enrollment: 2019 Nov 22
- A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Start of enrollment: 2022 Feb 17
Roles: Principal Investigator, Contact
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] Start of enrollment: 2018 Jun 27
Roles: Contact
Publications & Presentations
PubMed
- Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.Andrew B Katims, Charlie White, Syed Muneeb Alam, Mark Farha, Sadra Sepehri
Clinical Cancer Research. 2026-05-01 - 1 citationsNeoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, Jie-Fu Chen, Ronak H Shah
Clinical Cancer Research. 2026-04-15 - Combination Strategies to Enhance Bacillus Calmette-Guérin Efficacy for Nonmuscle-Invasive Bladder Cancer.Gal Wald, Jacob Lang, Hassan Alkazemi, Ao Zhang, Malik Wahba
The Journal of Urology. 2026-03-01
Press Mentions
Breakthrough Discoveries in Bladder Cancer Treatment Pave the Way for Enhanced ImmunotherapiesMay 29th, 2025- New Understanding of a Decades-Old Bladder Cancer Treatment Could Help Improve Immunotherapies More BroadlyMay 29th, 2025
- BCG Immunotherapy Reprograms Bone Marrow to Boost Cancer DefenseMay 28th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
